A proven, comfortable interface ready for your patient and their wound, regardless of what stands in the way.
UNIQUE TLC TECHNOLOGY PROMOTES HEALING
WHICH TLC DRESSING IS RIGHT FOR MY PATIENT’S WOUND?
Do you need to defend what does belong or attack what doesn’t belong?
The TLC dressings have the ability to adapt to any changes in moisture level between your dressing changes.
If the moisture level is low, the interface can retain fluid. If the moisture is too high, the TLC dressings allow the excess to pass through the dressing, thus repelling the excess fluid.
The only hydrophilic interface on the market providing you the best of both worlds.
ATRAUMATIC AND PAIN-FREE REMOVAL
Due to its unique design that retains its integrity over time, the TLC matrix allows for a pain-free and atraumatic removal process, giving your patient the best outcomes to facilitate wound progress.
Character of lesions following dressing removal1
Significant absence of lesions after removal, up to 8 days
Eradication of fibroblasts and of the extracellular matrix after removal
Clinical consequences at removal
With TLC Restoring Matrix (UrgoTul)
Eradication of fibroblasts with traditional gauze after removal
UrgoTul was associated with no or less pain at dressing change2
Acceptability of TLC dressing (UrgoTul)3
UrgoTul range is clinically proven in more than 11,600 patients4
1-year-old child presenting with a partial-thickness burn on the inside of the arm; after 15 days of treatment with UrgoTul, the wound has fully epithelialized5
13-month-old presenting with a traumatic wound on the forehead following a traffic accident; after 7 days the wound was healed5
CELLULAR INTEGRITY WITH URGOTUL
UrgoTul range is clinically proven to provide a nuturing environment for healing and harm-free care for your patient
Cellular morphology - confocal microscopy (72 h)1,6,7
Assessment of fibroblast proliferation
Effects on the synthesis of hyaluronic acid8
Effects on the production/release of soluble (pro)-collagen I8
INFECTION CONTROL WITH
UrgoTul Ag is clinically proven to facilitate wound progress, with reduced signs of local infection over neutral dressings8
Randomized controlled trial, multicentered
102 Patients RCT, 2 groups (sequential group): UrgoTul Ag/UrgoTul; neutral group: UrgoTul
Leg ulcers presenting signs suggesting heavy bacteria load
A significantly lower clinical score with the sequential TLC-Ag group
A very good safety profile of the TLC-Ag dressing
The TLC-Ag dressing did not induce any increase in blood silver levels in the patients checked
47.9% wound surface reduction with the sequential TLC-Ag group (P=0.036)
For more in-depth information about the UrgoTul and UrgoTul Ag difference, please see the following resources and product brochures.
1. Study report No. S/2003-007/BIOalternatives 2. Meaume S, et al. The importance of pain reduction through dressing selection in routine wound management: the MAPP study. J Wound Care. 2004;13(10):409-13. 3. Benbow M., losson, G. A clinical evaluation of UrgoTul to treat acute and chronic wounds. Br J Nurs. 2004;13(2):105-9. 4. White, R., Cowan, T., Glover, D. Supporting evidence-based practice: review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London 2015. 5. Le Touze A, et al. Interest of a new dressing (UrgoTul) in the management of wounds in a pediatric setting: results from a european clinical study. Poster, CPC 2005, Paris. 6. Bernard FX et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloid dressing. J Wound Care. 2005;14(5):215-20. 7. M. Le Berre, Y. Lurton et al., Coated dressings: gauzes/contact layers. Oral communication, CPC 2005, Paris. 8. Bernard FX et al. Effects of a lipidcolloid dressing on the production of the extracellular matrix. Journal des Plaies et Cicatrisations, 2007 (study conducted on UrgoTul).